These results suggest that clusterin deficiency promotes NLRP3 inflammasome activation during cholestasis and exacerbates NLRP3 inflammasome activation upon BDL, highlighting the key role of clusterin in modulating liver disease responses in different models of liver injury. Here, CLU is linked to cholestasis.